Company Overview and News

 
Stock market dips Felcra next? Stake sale must fulfill best practices

2018-10-13 thestar.com.my
THIS week has not been great for stocks. The Dow Jones and S&P 500 have had six consecutive days of straight declines with big plunges on Wednesday and Thursday.
5014 5222 CIMDF 1023 5347 5225 TNABY 6888 MYPRY AXXTF TNABF Q0F IHHHF

 
Bursa Malaysia ends broadly lower

2018-10-11 malaymail
KUALA LUMPUR, Oct 11 — Bursa Malaysia ended in the red amid broad selling activities and in line with Asian markets as investors remained on the sidelines on heightened volatility in the global markets, said a dealer.
GMALF 7036 4197 5199 GMALY 5225 4715 SMEBF Q0F BSMAF IHHHF HIPEF 1818

 
FBM KLCI down 1.54% as Wall Street tumble hits world markets

2018-10-11 theedgemarkets
KUALA LUMPUR (Oct 11): The FBM KLCI dropped 26.69 points or 1.54% today to end at 1,708.49 in tandem with Asian shares on what appeared to be a knee-jerk reaction to US stocks' overnight tumble.
GMALF UPBMF 2089 6033 CIMDF GMALY 1023 PNADF 5225 4715 Q0F IHHHF PNAGF

 
Bursa plunges at opening in face of global weakness

2018-10-11 malaymail
KUALA LUMPUR, Oct 11 — Bursa Malaysia extended its losses at the opening today in line with Wall Street’s weaker performance overnight on concerns over global growth prospects.
PBLOF 5225 5819 7036 Q0F 1295 BSMAF IHHHF HIPEF 1818 5199

 
Flurry of M&A activities

2018-10-10 thestar.com.my
KUALA LUMPUR: Malaysia could see a flurry of merger and acquisition (M&A) activities in the coming months, as the government looks to pare down direct ownership in companies to raise funds, according to the chief executive of CIMB Investment Bank.
1023 5347 5225 6888 TNABY AXXTF TNABF Q0F IHHHF CIMDF

 
CIMB expects flurry of M&A deals as govt eyes stake sales

2018-10-10 theedgemarkets
KUALA LUMPUR (Oct 10): Malaysia could see a flurry of merger and acquisition (M&A) activity in the coming months as the government looks to pare down direct ownership in companies to raise funds, the chief executive of CIMB Investment Bank said.
5347 5225 6888 TNABY AXXTF TNABF Q0F IHHHF

 
Bursa Malaysia ends lower

2018-10-09 malaymail
KUALA LUMPUR, Oct 9 — Bursa Malaysia ended in the red today in line with the weaker performance in most regional markets on lack of positive catalysts, said a dealer.
PBLOF UPBMF BATS 4162 1295 2089 5256 5199 5225 5819 Q0F BSMAF IHHHF HIPEF 1818

 
From Tata to Satyam, the shocking exits of top company execs that rocked corporate India

2018-10-09 moneycontrol
The resignation of CEO and MD of ICICI Bank Chanda Kochhar, amid conflict of interest allegations, shocked the banking sector recently. A whistle-blower had had alleged that ICICI Bank granted loans to Videocon Group, whose promoter Venugopal Dhoot had investments in NuPower Renewables, owned by the banker's husband Deepak Kochhar. The incident has brought back memories of top company executives who have stepped down over controversies.
YESBANK AXB IBN ALBK 532648 YYBKY 532215 AXBKY AXBA ICICIBANK 5225 PNJZY 532461 AXISBANK 532174 532480 PNB Q0F IHHHF

 
Digital healthcare service seen positive for sector

2018-10-09 theedgemarkets
Healthcare sector Maintain positive: Malaysia’s public spending on healthcare as a percentage of gross domestic product (GDP) has breached 4% since 2015. Nonetheless, with the current rate at about 4.4%, it is still one of the lowest in the region. To put things into perspective, Malaysia’s neighbouring emerging economies such as Cambodia and the Philippines recorded higher healthcare expenditure as a percentage of GDP at a rate close to 6% of their GDP.
KPJHF 5225 5878 Q0F IHHHF

 
KL shares open marginally lower on lack of fresh leads

2018-10-09 malaymail
KUALA LUMPUR, Oct 9 — Bursa Malaysia opened marginally lower on lack of fresh leads and in line with the lacklustre performance of regional markets.
PBLOF 5225 7108 5819 7036 1295 Q0F BSMAF IHHHF 5256 GEBHF 1818

 
Trading ideas: T7 Global, Reach Energy, IHH Healthcare

2018-10-09 thestar.com.my
KUALA LUMPUR: JF Apex Research expects T7 Global Bhd , Reach Energy Bhd and IHH Healthcare Bhd to be among the stocks to watch following their latest news.
5225 Q0F IHHHF 5256

 
CIMB Research positive on IHH strengthening Acibadem stake

2018-10-09 thestar.com.my
CIMB Equities Research is positive on IHH Healthcare’s move to consolidate its interest in Acibadem Saglik Yatirimlari Holdings (Acibadem) in Turkey to about 90%.
5225 Q0F IHHHF

 
IHH raises its stake in Acibadem Holdings to 90%

2018-10-08 thestar.com.my
PETALING JAYA: IHH Healthcare Bhd is raising its stake in Turkey-based healthcare group Acibadem Holdings by an additional 30%, bringing its stake to about 90%.
5225 Q0F IHHHF

 
KLCI to stay lacklustre, hurdle at 1,790

2018-10-08 theedgemarkets
KUALA LUMPUR (Oct 9): The FBM KLCI is expected to stay lacklustre today with immediate hurdle at 1,790-points, in line with the overnight fall at most global markets.
5148 5225 Q0F IHHHF 5256 0131

 
UEM Sunrise, T7, Reach Energy, MMC Corp, Gamuda, MCE Holdings and IHH Healthcare

2018-10-08 theedgemarkets
KUALA LUMPUR (Oct 8): Based on corporate announcements and news flow today, companies in focus on Tuesday (Oct 9) may include: UEM Sunrise Bhd, T7 Global Bhd, Reach Energy Bhd, MMC Corp Bhd, Gamuda Bhd, MCE Holdings Bhd and IHH Healthcare Bhd.
5148 5225 7245 Q0F IHHHF 5256 0131 5001

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...